Triple negative breast cancer: Clinical characteristics in the different histological subtypes

Breast

Volumn 22, Issue 5, 2013, Pages 761-766

  Dreyer, Geertje ^a   Vandorpe, Thijs ^a   Smeets, Ann ^a   Forceville, Kathleen ^a   Brouwers, Barbara ^a   Neven, Patrick ^a   Janssens, Hilde ^a   Deraedt, Karen ^a   Moerman, Philippe ^a   Van Calster, Ben ^a   Christiaens, Marie Rose ^a   Paridaens, Robert ^a   Wildiers, Hans ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Apocrine breast cancer; Breast cancer; Histology; Lymph node involvement; Outcome; Triple negative

Indexed keywords

ADULT; AGE; AGE DISTRIBUTION; AGED; ARTICLE; BELGIUM; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; COHORT ANALYSIS; DISEASE FREE INTERVAL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER; UNIVERSITY HOSPITAL;

APOCRINE BREAST CANCER; BREAST CANCER; HISTOLOGY; LYMPH NODE INVOLVEMENT; OUTCOME; TRIPLE NEGATIVE;

AGE FACTORS; AGED; CARCINOMA; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84884147792     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.01.009     Document Type: Article

References (29)

1. Global cancer fact & figures 2007 - American cancer Society.
2. Li C.I., Uribe D.J., Daling J.R. Clinical characteristics of different histologic types of breast cancer. Br J Cancer 2005, 93(9):1046-1052.
3. Yerushalmi R., Hayes M.M., Gelmon K.A. Breast carcinoma-rare types; review of the literature. Ann Oncol 2009, 20:1763-1770.
4. Schnitt S.J., Guidi A.J. Pathology of invasive breast cancer. Diseases of the breast 2004, 393. Lippincott, Williams and Wilkins, Philadelphia, PA. 3rd ed. J.R. Harris, M.E. Lippman, M. Morrow (Eds.).
5. Tavassoli F.A., Devilee P. World health organization classification of tumors, tumors of the breast and female genital organs 2003, IARC press, Lyon, France. 2nd ed.
6. Weigelt B., Reis-Filho J.S. Histological and molecular types of breast cancer: is there a unifying taxonomy?. Nat Rev Clin Oncol 2009, 6(12):718-730.
7. Jung S.Y., Kim H.Y., Nam B.H., Min S.Y., Lee S.J., Park C., et al. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat 2010, 120(3):627-637.
8. Yamaguchi R., Horii R., Maeda I., Suga S., Makita M., Iwase T., et al. Clinicopathologic study of 53 metaplastic breast carcinomas: their elements and prognostic implications. Hum Pathol 2010, 41(5):679-685.
9. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., et al. Race, breast cancer subtypes and survival in the carolina breast cander study. JAMA 2006, 295(21):2492-2502.
10. Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869.
11. Chukwuemeka U., Leffall L.D., Dewitty R.L., Naab T.J., Mezghebe H.M., Makambi K.H., et al. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. JSurg Res 2007, 143(1):109-118.
12. Zaha D.C., Lazar E., Lazureanu C. Clinicopathologic features and five years survival analysis in molecular subtypes of breast cancer. Rom J Morphol Embryol 2010, 51(1):85-89.
13. Voduc K.D., Cheang M.C.U., Tyldesley S., Gelmon K., Nielsen T.O., Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. JCO 2010, 28(10):1684-1691.
14. Kreike B., Van Kouwenhove M., Horlings H., Weigelt B., Peterse H., Bartelink H., et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007, 9(5):R65.
15. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13(15Pt1):4429-4434.
16. Haffty B.G., Yang Q., Reiss M., Kearny T., Higgins S.A., Weidhaas J., et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. JCO 2006, 24(36):5652-5657.
17. Bosch A., Eroles P., Zaragoza R., Viña J.R., Lluch A. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 2010, 36(3):206-215.
18. Thike A., Cheok P.Y., Jara-Lazaro A.R., Tan B., Tan P., Tan P.H. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 2010, 23(1):123-133.
19. Criscitiello C., Azim H.A., Schouten P.C., Linn S.C., Sotiriou C. Understanding the biology of triple-negative breast cancer. Ann Oncol 2012, 23(Suppl. 6):vi13-vi18.
20. Corkery B., Crown J., Clynes M., O'Donovan M. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 2009, 20:862-867.
21. O'Shaughnessy J., Osborne C., Pippen J., Yoffe M., Patt D., Monaghan G., et al. Efficay of BSI-201, a poly (ADPribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. JClin Oncol 2009, (meeting abstracts) 27:(abstr 3).
22. Gluz O., Liedtke C., Gottschalk N., Pusztai L., Nitz U., Harbeck N. Triple negativebreast cancer - current status and future directions. Ann Oncol 2009, 20:1913-1927.
23. Pal S.K., Mortimer J. Triple negative breast cancer: novel therapies and new directions. Maturitas 2009, 63(4):269-274.
24. Wildiers H., Van Calster B., Van de Poll-Franse L.V., Hendrickx W., Røslien J., Smeets A., et al. Relationship between age and axillary lymph node involvement in women with breast cancer. JClin Oncol 2009, 27(18):2931-2937.
25. Elston E.W., Ellis I.O. Method for grading breast cancer. JClin Pathol 1993, 46:186-190.
26. Van Calster B., Vanden Bempt I., Drijkoningen M., Pochet N., Cheng J., Van Huffel S., et al. Axillary lymph node status of operable breast cancers by combined steroid receptors and HER-2 status: triple positive tumours are more likely lymph node positive. Breast Cancer Res Treat 2009, 113:181-187.
27. Tumors of the breast and female genital organs 2003, IARC Press, Lyon. F. Tavassoli, P. Devilee (Eds.).
28. Vranic S., Tawfik O., Palazzo J., Bilalovic N., Eyzaguirre E., Lee L., et al. EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod Pathol 2010, 23(5):644-653.
29. Grambsch P., Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994, 81:515-526.